Physician profile
Eric R B Spronz
NPI 1922332261
$448,006.32
in general payments reported to CMS, 2019-2025
28 companies · $109K in 2025
The $109K reported for 2025 was more than what 99% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42K · 2022: $109K · 2023: $111K · 2024: $77K · 2025: $109K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $229K · Consulting Fee: $28K · Travel and Lodging: $23K · Food and Beverage: $16K · Honoraria: $150 · Education: $75.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $229,192.00 |
| Consulting Fee | $28,355.50 |
| Travel and Lodging | $22,923.24 |
| Food and Beverage | $15,687.02 |
| Honoraria | $150.00 |
| Education | $75.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $411,181.42 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $16,178.81 | 2021-2025 | Rexulti, Nuedexta |
| Abbvie INC. | $8,908.34 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $4,771.01 | 2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $1,033.05 | 2021-2025 | Nuplazid |
| Lundbeck LLC | $870.76 | 2021-2025 | Rexulti, Abilify Maintena |
| Harmony Biosciences LLC | $806.07 | 2021-2025 | Wakix |
| Alkermes, INC. | $786.22 | 2022-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $677.17 | 2022-2025 | Sunosi, Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $438.45 | 2021-2023 | Trintellix |
| Kyowa Kirin, INC. | $350.55 | 2021-2024 | Nourianz |
| Janssen Scientific Affairs, LLC | $230.00 | 2024-2025 | Spravato |
| Biogen, INC. | $215.03 | 2021-2023 | |
| Avanir Pharmaceuticals, INC. | $209.57 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $205.10 | 2021-2025 | Uzedy, Austedo, Austedo Xr |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $189.41 | 2023-2025 | Fanapt, Hetlioz |
| Jazz Pharmaceuticals INC. | $172.77 | 2022 | |
| H2-Pharma, LLC | $150.00 | 2025 | |
| Janssen Pharmaceuticals, INC | $117.67 | 2022-2023 | Spravato |
| Lilly USA, LLC | $113.41 | 2024-2025 | Kisunla, Amyvid, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $112.12 | 2022-2025 | Caplyta |
| Almatica Pharma LLC | $69.39 | 2022-2023 | Loreev Xr |
| Idorsia Pharmaceuticals US INC | $57.67 | 2022-2023 | Quviviq |
| Eisai INC. | $51.80 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $46.65 | 2024 | Rexulti |
| Bausch Health US, LLC | $26.97 | 2021 | |
| Alfasigma USA, INC. | $18.65 | 2021 | |
| Novo Nordisk INC | $18.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Spronz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.